论文部分内容阅读
目的:探讨重组人促血小板生成素(rhTPO)治疗西宁地区急性白血病化疗后血小板减少患者中的临床治疗效果。方法:选取2009年2月—2016年2月我院收治的急性白血病化疗后血小板减少患者资料进行分析,根据不同治疗方案将患者分为对照组和观察组,对照组采用重组人白介素-11(rhIL-11)治疗,观察组采用重组人促血小板生成素治疗,观察两组血小板变化情况及不良反应发生率。结果:观察组患者血小板计数<50×109/L的持续时间,恢复至70×109/L和恢复至100×109/L时间显著短于对照组(P<0.05);观察组不良反应发生率为10.0%,显著低于对照组(不良反应发生率为16.7%)(P<0.05)。结论:西宁地区急性白血病化疗后血小板减少患者采用重组人促血小板生成素(rhTPO)治疗效果理想,值得推广使用。
Objective: To investigate the clinical efficacy of recombinant human thrombopoietin (rhTPO) in the treatment of thrombocytopenia in patients with acute leukemia after chemotherapy in Xining. Methods: The data of patients with thrombocytopenia after acute leukemia treated in our hospital from February 2009 to February 2016 were analyzed. The patients were divided into control group and observation group according to different treatment plans. The control group was treated with recombinant human interleukin-11 rhIL-11). The observation group was treated with recombinant human thrombopoietin. The changes of platelet and the incidence of adverse reactions in the two groups were observed. Results: The duration of platelet count <50 × 109 / L, recovery to 70 × 109 / L and recovery to 100 × 109 / L in observation group were significantly shorter than those in control group (P <0.05). The incidence of adverse reactions in observation group Was 10.0%, significantly lower than the control group (adverse reaction rate was 16.7%) (P <0.05). CONCLUSION: Recombinant human thrombopoietin (rhTPO) in patients with thrombocytopenia after acute leukemia chemotherapy in Xining area is effective and worthy of promotion.